Systems biology of Ebola virus and Lassa virus determinants of infection outcome
Systems biology of Ebola virus and Lassa virus determinants of infection outcome
批准号:
10374720
负责人:
Kristian Graugaard Andersen
金额:
$42.5万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-02-01 至 2023-01-31
关键词:
Adaptive Immune SystemAffectAfricaAnimal ModelAntibodiesAreaCase Fatality RatesCatalogsCellsClinicalCommunicable DiseasesComplementComputer ModelsContainmentDataData SetDevelopmentDiseaseDisease OutcomeEbolaEbola Hemorrhagic FeverEbola virusEpitopesFutureGenerationsGeneticGenotypeGlycoproteinsGoalsHumanImmuneImmune EvasionIndividualInfectionIntegration Host FactorsInvestigationLassa FeverLassa virusLeadLinkMissionModelingMolecularMutationOutcomePatientsPersonsPlayProcessRiskRodentRoleSeroprevalencesSeveritiesSeverity of illnessSuggestionSurvivorsSystemSystems BiologyTechnologyTestingTherapeuticViralViral Hemorrhagic FeversVirusVirus Diseasesantibody engineeringassociated symptombaseco-infectioncohortcostdeep sequencingexperimental studyfitnessgenomic datahuman diseasehuman pathogeninsightpathogenpredictive markerpredictive modelingtechnological innovationtransmission processviral genomicsvirus genetics
中文摘要
项目摘要/摘要:
拉萨病毒和埃博拉病毒是最具破坏性的人类疾病病原体和人类感染病毒中的两种,这两种病毒都可以。
导致严重的出血热,病例死亡率超过70%。据估计,这将导致数十万人死亡。
每年有数以千计的人死于埃博拉病毒热。尽管埃博拉病毒的住院病例和死亡率很高,但仍有数千人死亡。
对于发烧的患者,如果没有无症状的感染或轻微的有症状的感染在中国发生的可能性很大,这是众所周知的。
拉萨病毒和埃博拉病毒都是如此。我们都知道,病毒和遗传学在决定疾病严重程度方面发挥着关键作用。
然而,这些机械性的研究仍然缺乏真知灼见,而且还没有进行过任何系统性的研究,以帮助识别病毒。
与人类疾病的发病率相关。同样,拉萨病毒热病和埃博拉病毒幸存者中有很高比例的人会发展成严重的疾病。
长期的癌症症状与他们的新疾病有关,但病毒感染因素可能无法确定这些新的并发症。
仍然难以捉摸。
这个研究项目的核心假设是,在拉萨病毒和埃博拉病毒中发现的fic基因因子是至关重要的。
在fl,感染和结果。我们直接与独一无二的拉萨病毒和埃博拉病毒患者和幸存者进行合作。
在西非,我们将无法确定拉萨病毒和埃博拉病毒的影响因素,这些都是人类疾病的决定因素。
我们将整合高通量技术和“组学”技术方法,包括高遏制技术、实验技术和计算技术。
建模有助于阐明决定传染性疾病严重程度的分子遗传网络。我们基于这些fi编码。
我们还将建立一些预测性的风险模型,这些模型不能用来确定感染拉萨病毒和感染埃博拉病毒的风险。
我们将通过完成这三个压倒性的目标来实现这些目标。在规范fi和目标1中,我们将继续创造新的目标和目标。
分析大规模的拉萨病毒和埃博拉病毒的基因组数据集,以及新感染的患者的基因和基因分型。
对这些病毒如何进化进行深入的研究,因为它们可能会将病毒从它们主要的天然水库传播给人类。
而人与人之间的关系决定了ff能在多大程度上影响临床治疗结果。在我们的专业中,fi的目标是2,我们将继续努力。
在功能上,以一种非常高吞吐量的方式,描述单个拉萨病毒和两种埃博拉病毒的变异。
最后,我们假设flfi的目标是3,我们将不会在高水平上进行我们的实验。
遏制措施是为了进一步确定功能正常的ff对拉萨病毒和埃博拉病毒的个体基因突变的影响。
研究人类免疫系统逃逸和感染的机制。作为实现这一目标的一部分,我们还将研究基因工程抗体。
更好地针对这两种病毒,这可以作为未来治疗的起点。
英文摘要
Project Summary / Abstract
Lassa virus and Ebola virus are two of the most devastating human pathogens and infection with both can
lead to severe hemorrhagic fever with case fatality rates in excess of 70%. It is estimated that tens of
thousands of people die from Lassa fever each year. Despite the high case fatality rates of hospitalized Ebola
and Lassa fever patients, it is well established that asymptomatic or mildly symptomatic infections occur in
both Lassa fever and Ebola. We know that virus genetics play key roles in determining disease severity,
however, mechanistic insights are lacking and no systematic studies have been performed to identify virus
correlates of human disease. Similarly, a high proportion of Lassa fever and Ebola survivors develop serious
long-term symptoms associated with their disease, but virus factors that may determine these complications
remain elusive.
The central hypothesis of this project, is that specific genetic factors in Lassa and Ebola viruses critically
influence infection outcomes. Working directly with unique Lassa and Ebola patient and survivor cohorts in
West Africa, we will identify Lassa virus and Ebola virus factors that are determinants of human disease. We
will integrate high-throughput ‘omics’ approaches, high-containment experimentation, and computational
modeling to elucidate molecular networks that determine infectious disease severity. Based on these findings,
we will build predictive models that can be used to determine risk from Lassa virus and Ebola virus infection.
We will achieve these goals by completing three overarching goals. In Specific Aim 1, we will create and
analyze large-scale genomic data sets of Lassa and Ebola viruses, and genotype of infected patients. We will
perform deep investigations of how the viruses evolve as they transmit from their natural reservoirs to humans
and between humans, and determine how that can affect clinical outcomes. In Specific Aim 2, we will
functionally characterize, in a high-throughput manner, individual Lassa virus and Ebola virus mutations
hypothesized to influence infectious outcomes. Finally, in Specific Aim 3 we will perform experiments in high
containment to determine functional effects of individual mutations in Lassa virus and Ebola virus, and
investigate mechanisms of immune escape and infection. As part of this aim, we will also engineer antibodies
to better target both viruses, which can be used as a starting point for future therapeutics.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
West African Emerging Infectious Disease Research Center (WA-EIDRC)
-
批准号:10653441
-
项目类别:
-
资助金额:$184.89万
-
财政年份:2022
-
负责人:Kristian Graugaard Andersen
-
依托单位:
Consortium for Viral Systems Biology (CViSB)
-
批准号:10469781
-
项目类别:
-
资助金额:$59.71万
-
财政年份:2021
-
负责人:Kristian Graugaard Andersen
-
依托单位:
Consortium for Viral Systems Biology Administrative Core
-
批准号:10469782
-
项目类别:
-
资助金额:$59.71万
-
财政年份:2021
-
负责人:Kristian Graugaard Andersen
-
依托单位:
West African Emerging Infectious Disease Research Center (WA-EIDRC)
-
批准号:10440593
-
项目类别:
-
资助金额:$26.63万
-
财政年份:2021
-
负责人:Kristian Graugaard Andersen
-
依托单位:
West African Emerging Infectious Disease Research Center (WA-EIDRC)
-
批准号:10631738
-
项目类别:
-
资助金额:$35.86万
-
财政年份:2020
-
负责人:Kristian Graugaard Andersen
-
依托单位:
West African Emerging Infectious Disease Research Center (WA-EIDRC)
-
批准号:10910587
-
项目类别:
-
资助金额:$23.6万
-
财政年份:2020
-
负责人:Kristian Graugaard Andersen
-
依托单位:
West African Emerging Infectious Disease Research Center (WA-EIDRC)
-
批准号:10394323
-
项目类别:
-
资助金额:$174.99万
-
财政年份:2020
-
负责人:Kristian Graugaard Andersen
-
依托单位:
West African Emerging Infectious Disease Research Center (WA-EIDRC)
-
批准号:10842168
-
项目类别:
-
资助金额:$80.18万
-
财政年份:2020
-
负责人:Kristian Graugaard Andersen
-
依托单位:
West African Emerging Infectious Disease Research Center (WA-EIDRC)
-
批准号:10616665
-
项目类别:
-
资助金额:$174.13万
-
财政年份:2020
-
负责人:Kristian Graugaard Andersen
-
依托单位:
Consortium for Viral Systems Biology Administrative Core
-
批准号:10579082
-
项目类别:
-
资助金额:$7.5万
-
财政年份:2018
-
负责人:Kristian Graugaard Andersen
-
依托单位:
Consortium for Viral Systems Biology (CViSB)
-
批准号:10248803
-
项目类别:
-
资助金额:$25.0万
-
财政年份:2018
-
负责人:Kristian Graugaard Andersen
-
依托单位:
Systems biology of Ebola virus and Lassa virus determinants of infection outcome
-
批准号:10310606
-
项目类别:
-
资助金额:$11.52万
-
财政年份:2018
-
负责人:Kristian Graugaard Andersen
-
依托单位:
Consortium for Viral Systems Biology Administrative Core
-
批准号:10310601
-
项目类别:
-
资助金额:$7.29万
-
财政年份:2018
-
负责人:Kristian Graugaard Andersen
-
依托单位:
Project 2
-
批准号:10558424
-
项目类别:
-
资助金额:$64.26万
-
财政年份:2018
-
负责人:Kristian Graugaard Andersen
-
依托单位:
Consortium for Viral Systems Biology (CViSB)
-
批准号:10374714
-
项目类别:
-
资助金额:$255.0万
-
财政年份:2018
-
负责人:Kristian Graugaard Andersen
-
依托单位:
Consortium for Viral Systems Biology (CViSB)
-
批准号:10579081
-
项目类别:
-
资助金额:$45.0万
-
财政年份:2018
-
负责人:Kristian Graugaard Andersen
-
依托单位:
Administrative Core
-
批准号:10558419
-
项目类别:
-
资助金额:$31.68万
-
财政年份:2018
-
负责人:Kristian Graugaard Andersen
-
依托单位:
Consortium for Viral Systems Biology (CViSB)
-
批准号:10356250
-
项目类别:
-
资助金额:$45.0万
-
财政年份:2018
-
负责人:Kristian Graugaard Andersen
-
依托单位:
Systems biology of Ebola virus and Lassa virus determinants of infection outcome
-
批准号:10579087
-
项目类别:
-
资助金额:$7.5万
-
财政年份:2018
-
负责人:Kristian Graugaard Andersen
-
依托单位:
Center for Viral Systems Biology (CViSB)
-
批准号:10558418
-
项目类别:
-
资助金额:$265.04万
-
财政年份:2018
-
负责人:Kristian Graugaard Andersen
-
依托单位:
海外基金